Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to -$6000.0.

  • Celldex Therapeutics' Gains from Investment Securities fell 5000.0% to -$6000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$16000.0, marking a year-over-year decrease of 2307.69%. This contributed to the annual value of -$16000.0 for FY2024, which is 10025.08% down from last year.
  • As of Q3 2025, Celldex Therapeutics' Gains from Investment Securities stood at -$6000.0, which was down 5000.0% from -$2000.0 recorded in Q2 2025.
  • Celldex Therapeutics' Gains from Investment Securities' 5-year high stood at $6.4 million during Q3 2023, with a 5-year trough of -$7.1 million in Q4 2021.
  • For the 5-year period, Celldex Therapeutics' Gains from Investment Securities averaged around $984255.3, with its median value being -$1000.0 (2021).
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first crashed by 11111.11% in 2021, then soared by 63799240.0% in 2023.
  • Celldex Therapeutics' Gains from Investment Securities (Quarter) stood at -$7.1 million in 2021, then surged by 99.99% to -$1000.0 in 2022, then surged by 637992.4% to $6.4 million in 2023, then crashed by 100.06% to -$4000.0 in 2024, then tumbled by 50.0% to -$6000.0 in 2025.
  • Its Gains from Investment Securities was -$6000.0 in Q3 2025, compared to -$2000.0 in Q2 2025 and -$4000.0 in Q1 2025.